anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Etomidate
Trial phase: Phase 4
ATC code: N01AX07
SMILES: CCOC(=O)c1cncn1[C@H](C)c1ccccc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 194
Group description: Participants receiving etomidate
Eligibility criteria:
Inclusion Criteria:

Persons greater than 18yrs requiring rapid sequence intubation for any reason.

Exclusion Criteria:

Pregnant patients
Children under the age of 18
Patients with a known hypersensitivity to etomidate or ketamine
Intervention: Ketamine
Trial phase: Phase 4
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 204
Group description: Participants receiving ketamine
Eligibility criteria:
Inclusion Criteria:

Persons greater than 18yrs requiring rapid sequence intubation for any reason.

Exclusion Criteria:

Pregnant patients
Children under the age of 18
Patients with a known hypersensitivity to etomidate or ketamine
Intervention: Ibuprofen
Trial phase: Phase 4
ATC code: C01EB16 | G02CC01 | M01AE01 | M01AE14 | M01AE51 | M02AA13 | N02AJ08 | N02AJ19 | R02AX02
SMILES: CC(C)Cc1ccc(C(C)C(=O)O)cc1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 35
Group description: Ibuprofen 600 mg: Ibuprofen 600mg prescription, to be taken 1 tablet as needed every 6 hours for pain.
Eligibility criteria:
Inclusion Criteria:

English-speaking women
18 years or older
Access to cell phone with text-messaging capability/data
Receiving cervical preparation for induced abortion
Able to complete baseline survey on smartphone/tablet at screening visit

Exclusion Criteria:

History of opioid or alcohol abuse
Contraindications or allergy to ibuprofen
Contraindications or allergy opioid medications
Seeking uterine evacuation for premature preterm rupture of membranes or advanced - cervical dilation or intrauterine fetal demise
Intervention: NIACIN
Trial phase: Phase 3
ATC code: C04AC01 | C10AD02 | C10AD52 | C10BA01
SMILES: O=C(O)c1cccnc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 32
Group description: 0.4% stannous fluoride preventive gel
Eligibility criteria:
Inclusion Criteria:

Provide written informed consent prior to participation and be given a signed copy of the informed consent form;
Be 18 years of age or older;
Agree not to participate in any other oral/dental product studies during the study;
Agree to delay any elective dentistry (including dental prophylaxis) until the study has been completed;
Agree to refrain from the use of any non-study oral hygiene products (subjects who are regular flossers will be allowed to floss during acclimation and wash-out periods);
Agree to use an oral hygiene product that contains stannous fluoride;
Agree to refrain from any form of non-specified oral hygiene during the treatment period, including the use of products such as floss, toothpicks for plaque removal, and chewing gum;
Agree to refrain from any oral hygiene, eating and drinking after 11:00 PM the evening before plaque measurements on Day 0 and Day 4 of the treatment periods;
Agree to return for all scheduled visits and follow study procedures;
Possess a minimum of 20 natural teeth with scorable facial and lingual surfaces, of which at least 4 are molars; and,
Be in good general health, as determined by the Investigator/designee based on a review of the health history/update for participation in the study.

Exclusion Criteria:• Have a medical condition requiring pre-medication prior to dental procedures;

Have taken antibiotics within 2 weeks of the acclimation period or anticipate taking antibiotics at any time during the study;
Have a history of allergies or hypersensitivity to dyes or dentifrices that contain stannous fluoride;
Have removable or orthodontic appliances which interfere with obtaining 20 gradable teeth;
Have previously demonstrated an inability to comply with study visit requirements;
Have rampant caries, open or untreated caries, severe gingivitis or advanced periodontitis requiring prompt treatment; or,
Present with any disease or condition(s) that could be expected to interfere with examination procedures or the subject's safe completion of the study.
Intervention: Tenofovir
Trial phase: Phase 2
SMILES: C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 28
Group description: tenofovir treatment for 48 weeks

Tenofovir: tenofovir disoproxil 245 mg, equivalent to tenofovir disoproxil fumarate 300 mg
Eligibility criteria:
Inclusion Criteria:

Age from 18 to 65 years inclusively at the time of signing Informed Consent Form.
Positive serum HBsAg for at least 6 months before Screening.
Positive serum anti-HDV antibody for at least 6 months before screening.
Positive PCR results for serum HDV RNA at Screening.
Patients with liver cirrhosis, irrespective of previous interferon treatment .
Patients without liver cirrhosis, who failed prior interferon treatment or for whom, in the opinion of the Investigator, such treatment is currently contraindicated (including history of interferon intolerance) .
Alanine aminotransferase level >1 x ULN, but less than 10 x ULN.
Previous nucleotide/nucleoside analogue treatment within at least 12 weeks prior to the planned start of study treatment or subject's willingness to take tenofovir for at least 12 weeks prior to the planned start of study treatment.
Negative urine pregnancy test for females of childbearing potential.

Inclusion criteria for female subjects:

Postmenopausal for at least 2 years, or
Surgically sterile (total hysterectomy or bilateral oophorectomy, bilateral tubal ligation, staples, or another type of sterilization), or
Abstinence from heterosexual intercourse throughout the study, or
Willingness to use highly effective contraception throughout the study and for 3 months after the last dose of the study medication.
Male and female subjects must agree to use a highly effective contraception throughout the study and for 3 months after the last dose of the study medication.
Male subjects must agree not to donate sperm throughout the study and for 3 months after the last dose of the study medication.

Exclusion Criteria:

Child-Pugh score of B-C or over 6 points.
HCV or HIV coinfection. Subjects with anti-HCV antibodies can be enrolled, if screening HCV RNA test is negative.
Creatinine clearance <60 mL/min.
Total bilirubin ≥ 2mg/dL. Patients with higher total bilirubin values may be included after the consultation with the Study's Medical Monitor, if such elevation can be clearly attributed to Gilbert's syndrome associated with low-grade hyperbilirubinemia.
Any previous or current malignant neoplasms, including hepatic carcinoma.
Intervention: Brexpiprazole
Trial phase: Phase 3
ATC code: N05AX16
SMILES: O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 73
Group description: Participants followed a titration schedule, to gradually increase their dose from 0.5 mg/day in the starting to 2 mg/day from Day 15. Participants continued to receive brexpiprazole 2 mg, once daily until Week 12.
Eligibility criteria:
Inclusion Criteria:

Participants with a diagnosis of probable Alzheimer's disease.
Participants with a diagnosis of agitation
Participants with a MMSE score of 5 to 22, inclusive, at screening and baseline visits.
Participants with a previous MRI or CT scan of the brain, that was performed after the onset of symptoms of dementia, with findings consistent with a diagnosis of Alzheimer's disease.
Participants who are residing at their current location for at least 28 days before screening and are expected to remain at the same location for the duration of the trial.
Institutionalized participants with an identified caregiver who has sufficient contact (minimum of 2 hours per day for 4 days per week) to describe the participant's symptoms and has direct observation of the participant's behavior. Non-institutionalized participants may not be living alone and must have an identified caregiver who has sufficient contact (minimum of 2 hours per day for 4 days per week) to describe the participant's symptoms and has direct observation of the participant's behavior.
Participants with onset of symptoms of agitation at least 2 weeks prior to screening visit.
Participants will and able to discontinue all prohibited concomitant medications to meet protocol required washouts prior to and during the trial period.

Exclusion Criteria:

Participants with dementia or other memory impairment not due to Alzheimer's disease.
Participants with a history of stroke, well-documented transient ischemic attack, or pulmonary or cerebral embolism.
Participants who had an insufficient response, based on the investigator's judgment, to 2 or more previous antipsychotic medications.
Participants who have been diagnosed with an Axis I disorder.
Participants who currently have clinically significant neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, gastrointestinal, or psychiatric disorders.
Participants with uncontrolled hypertension or symptomatic hypotension, or orthostatic hypotension.
Participants with diabetes mellitus (insulin-dependent and non-insulin-dependent) may be eligible for the trial if their condition is stable and well-controlled.
Intervention: Brexpiprazole
Trial phase: Phase 3
ATC code: N05AX16
SMILES: O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 153
Group description: Participants followed a titration schedule, to gradually increase their dose from 0.5 mg/day in the starting to 3 mg/day from Day 29. Participants continued to receive brexpiprazole 3 mg, once daily until Week 12.
Eligibility criteria:
Inclusion Criteria:

Participants with a diagnosis of probable Alzheimer's disease.
Participants with a diagnosis of agitation
Participants with a MMSE score of 5 to 22, inclusive, at screening and baseline visits.
Participants with a previous MRI or CT scan of the brain, that was performed after the onset of symptoms of dementia, with findings consistent with a diagnosis of Alzheimer's disease.
Participants who are residing at their current location for at least 28 days before screening and are expected to remain at the same location for the duration of the trial.
Institutionalized participants with an identified caregiver who has sufficient contact (minimum of 2 hours per day for 4 days per week) to describe the participant's symptoms and has direct observation of the participant's behavior. Non-institutionalized participants may not be living alone and must have an identified caregiver who has sufficient contact (minimum of 2 hours per day for 4 days per week) to describe the participant's symptoms and has direct observation of the participant's behavior.
Participants with onset of symptoms of agitation at least 2 weeks prior to screening visit.
Participants will and able to discontinue all prohibited concomitant medications to meet protocol required washouts prior to and during the trial period.

Exclusion Criteria:

Participants with dementia or other memory impairment not due to Alzheimer's disease.
Participants with a history of stroke, well-documented transient ischemic attack, or pulmonary or cerebral embolism.
Participants who had an insufficient response, based on the investigator's judgment, to 2 or more previous antipsychotic medications.
Participants who have been diagnosed with an Axis I disorder.
Participants who currently have clinically significant neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, gastrointestinal, or psychiatric disorders.
Participants with uncontrolled hypertension or symptomatic hypotension, or orthostatic hypotension.
Participants with diabetes mellitus (insulin-dependent and non-insulin-dependent) may be eligible for the trial if their condition is stable and well-controlled.
Intervention: Semaglutide
Trial phase: Phase 3
ATC code: A10BJ06
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1306
Group description: Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg Semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing Semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg Semaglutide once weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced-calorie diet and increased physical activity.
Eligibility criteria:
Inclusion Criteria:

Main phase:

Male or female, age greater than or equal to 18 years at the time of signing informed consent
Body mass index (BMI) greater than or equal to 30.0 kg/sqm or greater than or equal to 27.0 kg/sqm with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease
History of at least one self-reported unsuccessful dietary effort to lose body weight

Extension phase:

Informed consent for the extension phase obtained before any trial related activities for the extension phase
On randomised treatment on the target dose at week 68, i.e. treated with 2.4 mg semaglutide once-weekly or semaglutide placebo

Exclusion Criteria:

Main phase:

Glycated haemoglobin (HbA1C) greater than or equal to 48 mmol/mol (6.5%) as measured by the central laboratory at screening
A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records

Extension phase:

Female who is pregnant or intends to become pregnant during the extension phase
Any disorder, unwillingness or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardise the subject's compliance with the extension of the trial
Intervention: Valsartan
Trial phase: Phase 3
ATC code: C09CA03 | C09DA03 | C09DB01 | C09DB08 | C09DX01 | C09DX02 | C09DX04 | C09DX05 | C10BX10
SMILES: CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 46
Group description: 40mg (dose level 1), 80mg (dose level 2) and 160mg (dose level 3) twice daily.

Valsartan: is an angiotensin II receptor antagonist (commonly called an ARB, or angiotensin receptor blocker), that is selective for the type I (AT1) angiotensin receptor.
Eligibility criteria:
Inclusion Criteria:

Acute myocardial infarction (AMI) at least 3 months prior to recruitment

Left ventricular ejection ≤40% as measured by transthoracic echocardiography
Ability to provide written, informed consent
Age ≥18 years
Tolerance of a minimum dose of ACE inhibitor/ARB (ramipril 2.5mg BD or equivalent)
Treatment with a beta-blocker unless not tolerated or contraindicated.

Exclusion Criteria:

Contraindication to CMR (ferrous prosthesis, implantable cardiac device or severe claustrophobia)

Clinical and/or radiological heart failure (NYHA≥2)
Symptomatic hypotension and/or systolic blood pressure <100mmHg
eGFR < 30 mL/min/1.73m2 and/or serum potassium >5.2mmol/L
Persistent/permanent atrial fibrillation
History of AMI within last 3 months
History of hypersensitivity or allergy to ACE-inhibitors/ARB
History of angioedema
Known hypersensitivity to the active study drug substances, contrast media or any of the excipients
Obesity (where body girth exceeds MRI scanner diameter)
Pregnancy, planning pregnancy, or breast feeding
Inability to give informed consent or comply with study protocol
Evidence of hepatic disease as determined by any one of the following: AST or ALT values exceeding 2 x ULN at Visit 1, history of hepatic encephalopathy, history of oesophageal varices, or history of portacaval shunt
History of biliary cirrhosis and cholestasis
Active treatment with cholestyramine or colestipol resins
Active treatment with lithium or direct renin inhibitor
Participation in another intervention study involving a drug or device within the past 90 days (co-enrolment in observational studies is permitted)
Intervention: Ketamine
Trial phase: Phase 2 | Phase 3
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 16
Group description: 15 subjects undergoing ketamine general anesthesia.

Subjects' brain waves will be monitored by EEG recording under ketamine general anesthesia over the course of approximately 60 minutes. Patients pain and dissociation will be assessed before the induction of ketamine and periodically after. Approximately 1 hour after ketamine induction, Midazolam will be administered to reduce patient dissociation.
Eligibility criteria:
Inclusion Criteria:

Between the ages of 18 to 45
Normal body weight and habitus, BMI less than or equal to 30
Non-smoker
American Society of Anesthesiologists (ASA) physical status classification P1

Exclusion Criteria:

Cardiovascular: myocardial infarction, coronary artery disease, peripheral vascular disease, arrhythmia, congestive heart failure, valvular disease, hypertension
Respiratory: bronchitis, chronic obstructive pulmonary disease, smoking, shortness of breath
Hepatic: hepatitis, jaundice, ascites
Neurologic: seizure, stroke, positive neurologic findings on neurologic examination, multiple sclerosis, Meniere's disease, Parkinson's disease, neuropathy, peripheral stenosis
Gastrointestinal: esophageal reflux, hiatal hernia, ulcer
Endocrine: diabetes, thyroid disease
Renal: acute or chronic severe renal insufficiency
Hematologic: blood dyscrasias, anemia, coagulopathies, on anticoagulant therapy
Musculoskeletal: prior surgery or trauma to head neck or face, arthritis, personal or family history of malignant hyperthermia
Psychiatric: history or treatment for an active psychiatric problem, depression
Reproductive: pregnancy, breast-feeding
Medications: regular use of prescription and non-prescription medications expected to affect CNS function, St. John's Wort
Allergies: labetalol, ondansetron, glycopyrrolate, ketamine, midazolam
Intervention: Celecoxib
Trial phase: Phase 2
ATC code: C08CA51 | G01AE10 | L01XX33 | M01AH01 | N02AJ16
SMILES: Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Single dose containing 62.5 mg of celecoxib in 10 ml solution

DFN-15 (Celecoxib Oral Solution) 62.5 mg: Oral Solution
Eligibility criteria:
Inclusion Criteria:

Subjects scheduled to undergo elective bilateral lower (mandibular) third molar extraction under local anesthesia.
Subjects must be generally healthy, ambulatory, able to understand and willing to comply with study procedures, study restrictions, assessments, and requirements per the discretion of the investigator.
Subjects must voluntarily sign written informed consent prior to any study-specific procedures.
Subjects must have a body mass index (BMI) greater than or equal to 19.0 to less than or equal to 35.0

Exclusion Criteria:

History of migraine or frequent headaches, low back pain, or other acute or chronic pain conditions.
Acute illness or unresolved local infection prior to surgery that can interfere with the conduct of the study.
Positive results on urine drug screen or alcohol breath test indicative of illicit drug (Cocaine Metabolites, Marijuana (THC), MDMA (Ecstasy) and Phencyclidine) or alcohol abuse at screening and/or prior to extraction procedure.
Positive results for the following (prescription included): Amphetamines, Barbiturates, Benzodiazepines, Methadone, Methamphetamine, Opiates, Oxycodone, and Tricyclic Antidepressants.
Frequent use of nicotine-containing products.
Excessive intake of caffeine-containing foods or beverages within 48 hours prior to surgery.
Routinely uses pain medication.
Currently taking any corticosteroid chronically (except for an inhaled steroid for pulmonary disease, and local topical or ophthalmic steroid) or has taken systemic corticosteroids within 4 weeks of the proposed date of surgery.
Currently taking central nervous system active drugs such as hypnotics, sedatives, monoamine oxidase inhibitors, sympathomimetic amines, benzodiazepines, tricyclic antidepressants, or serotonin norepinephrine reuptake inhibitors, and anticonvulsants for pain.
Donated blood products or had blood loss greater than 500 mL 30 days prior to Screening or between Screening and surgery.
Member or relative of study staff or the Sponsor directly involved in the study.
Previous participation in this study.
Has received another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment within 30 days prior to the Screening visit.
Currently receiving or have received within 7 days prior to investigational product administration in the study, any drug (s) that is metabolized by hepatic microsomal enzyme CYP 2D6.
Clinically significant disease or disorder which may put the subject at risk, influence the results or the subject's ability to participate in the study.